 I. To compare the non-relapse mortality NRM and relapse related mortality RRM rates at 1 year for patients treated on this study to the that of patients undergoing haploidentical RIC hematopoietic stem cell transplantation HSCT as reported in the literature and as observed in the 2 step RIC trials. 